ストックスクリーナーアプリを入手
1.2589
4.68%
0.0589
Lexicon Pharmaceuticals Inc (LXRX) 最新ニュース
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
Lexicon Pharmaceuticals Scheduled to Release Q2 2025 Financial Results and Conduct Conference Call on August 6, 2025 - Quiver Quantitative
What drives Lexicon Pharmaceuticals Inc. stock pricePowerful market insights - jammulinksnews.com
Is Lexicon Pharmaceuticals Inc. a good long term investmentUnstoppable profit momentum - jammulinksnews.com
Lexicon Pharmaceuticals Inc. Stock Analysis and ForecastOver 200% growth - jammulinksnews.com
What analysts say about Lexicon Pharmaceuticals Inc. stockTremendous gains - Autocar Professional
H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - MSN
Lexicon Pharmaceuticals: A High-Potential Biotech Play in the Diabetes Space - AInvest
10 Hot Penny Stocks to Invest in Now - Insider Monkey
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) - The Manila Times
Lexicon Pharmaceuticals to Present Study on Diabetic Peripheral Neuropathic Pain at ASPN 2025 Conference - Quiver Quantitative
Revolutionary Non-Opioid Drug Could Help 100M People Suffering from Diabetic Nerve Pain - Stock Titan
What makes Lexicon Pharmaceuticals Inc. stock price move sharplyTop ROI Selections - beatles.ru
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap touched US$389m last week, benefiting both private equity firms who own 48% as well as institutions - simplywall.st
Lexicon Pharmaceuticals (LXRX) Soars 16.74% on Technical Signals - AInvest
Lexicon Pharmaceuticals Defies Expectations: What Lies Ahead? - StocksToTrade
Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension - The Globe and Mail
Lexicon Pharmaceuticals receives additional compliance period from Nasdaq - Investing.com
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm - ACCESS Newswire
While institutions own 28% of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), private equity firms are its largest shareholders with 48% ownership - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Congestive Heart Failure Market to Expand Significantly by 2034, States DelveInsight Report | Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, Merck Sharp & Dohme LLC, Corthera - Barchart.com
Lexicon Pharmaceuticals (LXRX) Receives Buy Rating from HC Wainwright & Co. | LXRX Stock News - GuruFocus
H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock By Investing.com - Investing.com Canada
Breakthrough: Sotagliflozin Cuts Dangerous Low Blood Sugar Events in Type 1 Diabetes Patients - Stock Titan
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) | LXRX Stock News - GuruFocus
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - TradingView
New Clinical Data Shows Lexicon's Diabetes Drug Effective Across All Kidney Function LevelsADA Conference - Stock Titan
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31% - simplywall.st
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple - MarketScreener
Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
Lexicon Pharmaceuticals at Jefferies Conference: Strategic Partnerships and Pipeline Progress - Investing.com Canada
Earnings call transcript: Lexicon Pharmaceuticals Q4 2024 beats EPS forecast By Investing.com - Investing.com UK
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Northern Trust Corp - Defense World
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - MSN
Lexicon Pharmaceuticals' Q1 2025: Unpacking Contradictions in Trial Designs, FDA Strategies, and Partnership Plans - AInvest
Lexicon (LXRX) Advances Study on Sotagliflozin for Heart Conditions | LXRX Stock News - GuruFocus
LXRXLexicon Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts - simplywall.st
Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Lexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo Nordisk - MSN
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - Insider Monkey
3.69%
0.28%
大文字化:
|
ボリューム (24 時間):